| Literature DB >> 33539064 |
Andrea Peier1, Lan Ge1, Nicolas Boyer2, John Frost1, Ruchia Duggal2, Kaustav Biswas2, Scott Edmondson1, Jeffrey D Hermes1, Lin Yan1, Chad Zimprich3, Ahmad Sadruddin4, Hung Yi Kristal Kaan4, Arun Chandramohan4, Christopher J Brown5, Dawn Thean5, Xue Er Lee5, Tsz Ying Yuen5, Fernando J Ferrer-Gago5, Charles W Johannes5, David P Lane5, Brad Sherborne1, Cesear Corona6, Matthew B Robers3, Tomi K Sawyer2, Anthony W Partridge4.
Abstract
Macrocyclic peptides open new opportunities to target intracellular protein-protein interactions (PPIs) that are often considered nondruggable by traditional small molecules. However, engineering sufficient membrane permeability into these molecules is a central challenge for identifying clinical candidates. Currently, there is a lack of high-throughput assays to assess peptide permeability, which limits our capacity to engineer this property into macrocyclic peptides for advancement through drug discovery pipelines. Accordingly, we developed a high throughput and target-agnostic cell permeability assay that measures the relative cumulative cytosolic exposure of a peptide in a concentration-dependent manner. The assay was named NanoClick as it combines in-cell Click chemistry with an intracellular NanoBRET signal. We validated the approach using known cell penetrating peptides and further demonstrated a correlation to cellular activity using a p53/MDM2 model system. With minimal change to the peptide sequence, NanoClick enables the ability to measure uptake of molecules that enter the cell via different mechanisms such as endocytosis, membrane translocation, or passive permeability. Overall, the NanoClick assay can serve as a screening tool to uncover predictive design rules to guide structure-activity-permeability relationships in the optimization of functionally active molecules.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33539064 DOI: 10.1021/acschembio.0c00804
Source DB: PubMed Journal: ACS Chem Biol ISSN: 1554-8929 Impact factor: 5.100